Orexo in collaboration with its advisory international law firms Potter Clarkson and Steptoe, will host a seminar on how to build robust patent strategies that will protect pharmaceutical IP even in the face of hostile generic opposition.
The session, targeting innovators, pharma companies, biotech firms and investors, will be delivered at Nordic Life Science Days’ conference in Gothenburg, Sweden, on Monday 13 October, at Flow Stage between 4.30-5.30 pm CEST. It will provide real life insight into how a company ultimately looking to sell their product in the US can build an IP strategy capable of successfully defending their position when they are inevitably challenged.
Orexo has successfully developed four drugs from concept to market, including Zubsolv® for opioid dependence, which is commercialized by Orexo in the US. The company has extensive experience in building robust patent strategies that support product development cycles. Orexo has demonstrably and repeatedly benefited from these strategies, including when its innovations have been challenged by leading international generic companies, such as Actavis/Teva in 2018 and, more recently, Sun Pharmaceutical Industries in December 2024.
In this session, key players behind Orexo’s success come together to provide their perspectives on the most recent case against Sun Pharmaceutical. Together, the panel will endeavor to provide the audience with an overview of how to successfully defend your commercial interests not only after, but well before, you reach the US market, given that much of the groundwork is typically laid years beforehand.
Speakers:
- Robert Rönn, SVP and Head of R&D at Orexo; Driving Innovation and Safeguarding Competitiveness through Robust IP Strategies
- Stephen McNeeney, Partner and pharmaceutical Patent expert at Potter Clarkson LLP; Partnering for Success – Potter Clarkson’s Role in Orexo’s US Market Achievements
- John Molenda, Partner at Steptoe LLP, Co-Chair of Steptoe’s Healthcare & Life Sciences Practice; From groundwork to Courtroom Success.
The presentations will be followed by a Q&A session during which guests can probe the panel about appropriate strategies for defending against the inevitable threat of generic litigation after US market entry.
Date: Monday, 13th October 2025
Time: 16:30 – 17:30
Venue: Svenska Mässan, Mässans Gata/Korsvägen, 412 94 Göteborg, Sweden